Grants Awarded



Click on any project title for a more detailed description of the project. For more information about any of these awards (e.g., PI contact information or associated publications), please use the corresponding project number to search for information at the NIH Reporter website. Consistent with NIH policy, abstracts are not available for projects receiving their first award within the past year, so descriptions provided below are from the NCI program director.

New awards will be posted as they are issued.

Year Award Type Project # RFA # PI/Project Leader Institution Title Statussort ascending
2000 R44 PAR-98-066 ANDERSON, N LEIGH LARGE SCALE BIOLOGY CORPORATION PROTEOMIC TECHNOLOGIES FOR CANCER RESEARCH Complete
2023 R61 RFA-CA-22-001 DHAKAL, SOMA VIRGINIA COMMONWEALTH UNIVERSITY Single-Molecule High-Confidence Detection of miRNA Cancer Biomarkers Active
2023 R33 RFA-CA-22-002 MEYER, KATHRYN D DUKE UNIVERSITY A High-Throughput Screening Platform to Discover RNA Methylation Inhibitors Active
2022 R21 CA21-005 BORGES, CHAD R ARIZONA STATE UNIVERSITY-TEMPE CAMPUS Aliquot-level visual indicators of biospecimen exposure to thawed conditions Active
2021 R21 RFA-CA-20-019 SANTORE, MARIA M UNIVERSITY OF MASSACHUSETTS AMHERST Paper-based Breastmilk Collection System for Facile, In-Home Use Active
2022 R33 RFA-CA-21-004 PAN, TAO UNIVERSITY OF CHICAGO Transfer RNA sequencing and application to cancer research and clinics Active
2022 R33 RFA-CA-21-004 WANG, TZA-HUEI JEFF JOHNS HOPKINS UNIVERSITY A low-cost, multiplexed digital high resolution melt platform for DNA methylation-based detection and identification of cancers in liquid biopsies Active
2022 R21 CA21-003 BOYLE, ALAN P UNIVERSITY OF MICHIGAN AT ANN ARBOR High-throughput inverted reporter assay for characterization of silencers and enhancer blockers Active
2021 R21 RFA-CA-20-017 WILSON, GERALD M UNIVERSITY OF MARYLAND BALTIMORE Suppressing oncogenic RNA regulons using engineered zinc finger ribonucleases Active
2023 R61 RFA-CA-22-001 LU, YUE UNIVERSITY OF UTAH Vesicle Epitope Transcript sequencing (VET-seq): Droplet-based Multiomic Profiling Platform for Single Vesicle Analysis Active
2022 R21 RFA-CA-21-005 TANG, SINDY KAM-YAN STANFORD UNIVERSITY A micro-dissection platform for generating uniform-sized patient-derived tumor organoids (PDOs) for personalized cancer therapy Active
2022 R21 CA21-003 SCARCELLI, GIULIANO UNIV OF MARYLAND, COLLEGE PARK Stimulated Brillouin Flow Cytometry for biomechanical assessment of metastatic potential Active
2021 R21 RFA-CA-20-017 ZHANG, FANGLIANG UNIVERSITY OF MIAMI SCHOOL OF MEDICINE Targeted degradation of proteins by affinity peptide conjugated ubiquitin (APCU) Active
2021 R43 PAR-18-303 ALLEN, JEFFREY KEITH TUMORGEN, INC. Capture and Characterization of Highly Metastatic Cancer Cell Clusters in Transit from Lung Cancer Patient Whole Blood Specimens. Active
2023 R61 RFA-CA-22-001 PRATX, GUILLEM STANFORD UNIVERSITY A Novel Assay to Individualize Resensitization of Iodine-Refractory Thyroid Cancer Active
2022 R33 CA21-004 NORMAN, THOMAS MAXWELL SLOAN-KETTERING INST CAN RESEARCH Systematic characterization of cancer variants using single-cell functional genomics Active
2021 R21 RFA-CA-20-017 STILL, AMANDA NICOLE HAYMOND GEORGE MASON UNIVERSITY New Hybrid Molecular Modalities Comprised of DNA-Origami and Interfering Peptides as Inhibitors of Protein-Protein Interactions Active
2022 R21 RFA-CA-21-003 GIBBS, SUMMER LYNNE OREGON HEALTH & SCIENCE UNIVERSITY A Novel Fluorescence Imaging Platform to Predict Response to Combinatorial Tyrosine Kinase Inhibitors Active
2022 R21 CA21-003 LEE, HAKHO MASSACHUSETTS GENERAL HOSPITAL 3D Fourier Imaging System for High Throughput Analyses of Cancer Organoids Active
2021 R21 RFA-CA-20-017 XIAO, HAN RICE UNIVERSITY Development of Bone-Targeting Antibodies for Ewing Sarcoma Using Genetic Code Expansion Active
2020 R33 RFA-CA-19-020 RECHT, MICHAEL PALO ALTO RESEARCH CENTER High-Throughput Screening Platform for Cancer Drug Discovery Active
2023 R61 RFA-CA-22-001 CAMPAGNOLA, PAUL J UNIVERSITY OF WISCONSIN-MADISON A novel multimodal ECM analysis platform for tumor characterization combining morphological and spectrochemical tissue imaging approaches. Active
2022 R21 CA21-003 BELCHER, ANGELA M MASSACHUSETTS INSTITUTE OF TECHNOLOGY A cell-cycle induced genetic recorder for simultaneous recovery of cell divisions and lineage Active
2021 R21 RFA-CA-20-017 SWAGER, TIMOTHY M MASSACHUSETTS INSTITUTE OF TECHNOLOGY Innovative Droplet Lenses for NextGen Light Sensors of Biomarkers of Inflammation Active
2021 R21 RFA-CA-20-017 BAR-PELED, LIRON MASSACHUSETTS GENERAL HOSPITAL Chemical Proteomic Identification of Druggable Oncogenic Transcription Factors Active
2023 R33 RFA-CA-22-004 DUNCAVAGE, ERIC J WASHINGTON UNIVERSITY A Rapid and Comprehensive Approach for Clinical Genomic Profiling in Lung Cancer Active
2022 R33 CA21-004 DRAKE, RICHARD R MEDICAL UNIVERSITY OF SOUTH CAROLINA Targeted Isolation and Identification of Sialylated Glycoproteins in Cancer Tissues, Cells and Biofluids Active
2021 R21 RFA-CA-20-017 CHEN, KAI UNIVERSITY OF SOUTHERN CALIFORNIA Novel Bisphosphonate PET Probes for Myeloma Bone Disease Active
2022 R33 RFA-CA-21-004 NAEGLE, KRISTEN M UNIVERSITY OF VIRGINIA A synthetic toolkit for the recombinant production of tyrosine phosphorylated proteins and peptides Active
2022 R21 CA21-003 ARMITAGE, BRUCE A CARNEGIE-MELLON UNIVERSITY Fluorescent gammaPNA Miniprobes for Imaging Telomeric RNA Active
2021 R33 RFA-CA-20-018 JI, HANLEE P STANFORD UNIVERSITY Multimodal iterative sequencing of cancer genomes and single tumor cells Active
2023 R33 RFA-CA-22-002 WEISSLEDER MD PHD, RALPH MASSACHUSETTS GENERAL HOSPITAL Bioorthogonal probe development for highly parallel in vivo imaging Active
2022 R21 CA21-003 COUNTER, CHRISTOPHER M DUKE UNIVERSITY Adapting K-MDS to detect KRAS-mutant ctDNA Active
2021 R33 RFA-CA-20-018 GARTNER, ZEV JORDAN UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Universal Sample Multiplexing for Single Cell Analysis Active
2023 R33 RFA-CA-22-002 VAN GALEN, PETER BRIGHAM AND WOMEN'S HOSPITAL Clonal analysis of cancer by mitochondrial DNA barcoding Active
2022 R33 CA21-004 MERAJVER, SOFIA DIANA UNIVERSITY OF MICHIGAN AT ANN ARBOR Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence Active
2021 R33 RFA-CA-20-020 HAUN, JERED BRACKSTON UNIVERSITY OF CALIFORNIA-IRVINE Microfluidic tumor tissue processing platform for single cell diagnostics Active
2023 R33 RFA-CA-22-002 ISSADORE, DAVID AARON UNIVERSITY OF PENNSYLVANIA Combining Machine Learning and Nanofluidic Technology for The Multiplexed Diagnosis of Pancreatic Adenocarcinoma Active
2022 R33 CA21-004 ADEY, ANDREW OREGON HEALTH & SCIENCE UNIVERSITY Accessible high-throughput single-cell genome sequencing Active
2021 R33 RFA-CA-20-018 SEELIG, GEORG UNIVERSITY OF WASHINGTON Joint receptor and protein expression immunophenotyping through split-pool barcoding Active
2023 R33 RFA-CA-22-004 LEVENSON, RICHARD M UNIVERSITY OF CALIFORNIA AT DAVIS CoreView and FIBI for rapid-onsite evaluation and molecular profiling of core-needle breast biopsies. Active
2022 R33 CA21-004 KARGINOV, ANDREI V UNIVERSITY OF ILLINOIS AT CHICAGO Optogenetic Control of Tumor Initiation and Tumor Progression in vivo Active
2021 R33 RFA-CA-20-018 GREENBERG, JOEL DUKE UNIVERSITY Multimodality X-ray transmission and diffraction scanner for molecular analysis of cancer specimens Active
2023 R61 RFA-CA-22-001 HACOHEN, NIR BROAD INSTITUTE, INC. Development of methods for highly multiplexed quantification of cancer proteomes using large-scale nanobody libraries Active
2022 R21 CA21-005 BORGES, CHAD R ARIZONA STATE UNIVERSITY-TEMPE CAMPUS Plate reader assays to forensically assess exposure of plasma and serum to thawed conditions Active
2021 R33 RFA-CA-20-018 HANSEN, ANDERS SEJR MASSACHUSETTS INSTITUTE OF TECHNOLOGY Super-resolution microscopy for dynamic analysis of focal enhancer amplifications in cancer Active
2022 R21 RFA-CA-21-003 SALIPANTE, STEPHEN J UNIVERSITY OF WASHINGTON Efficient, cost-effective, and ultrasensitive sequencing of somatic mutations Active
2022 R33 CA21-004 MOELLERING, RAYMOND E UNIVERSITY OF CHICAGO Single-Cell Protein Activity Profiling in Breast Cancer Cells and Tissues Active
2021 R33 RFA-CA-20-018 LIU, XUEFENG OHIO STATE UNIVERSITY Validating Urine Derived Cancer Cells (UDCC) -- Non-Invasive and Living Liquid Biopsies -- in Bladder Cancer Clinics Active
2020 R21 RFA-CA-19-019 ALEXANDRAKIS, GEORGIOS UNIVERSITY OF TEXAS ARLINGTON Nanotechnology Enabled Selection Of MHC-peptide Ligands To Personalize Cancer Therapy Active

Pages